Eltrombopag with i.v. immunoglobulin for safe splenectomy in refractory immune thrombocytopenia

Eltrombopag with i.v. immunoglobulin for safe splenectomy in refractory immune thrombocytopenia The first‐line treatment for pediatric immune thrombocytopenia (ITP) consists of observation, i.v. immunoglobulin (IVIG), or corticosteroids. Although these procedures resolve the condition in most affected children, some are refractory to treatment or relapse. Recent second‐line treatments, such as cyclosporin, rituximab or thrombopoietin receptor (TPO‐R) agonist are promising, but some patients do not respond well to them. Splenectomy remains the only salvage intervention that may induce a curative effect in nearly two‐thirds of such patients. We report a case of refractory ITP. The patient did not respond to first‐ and second‐line treatment. Concomitant use of eltrombopag and IVIG resulted in transient increase of platelet count and allowed a safer execution of splenectomy that resulted in remission of ITP. This is the first successful treatment of pediatric refractory ITP using TPO‐R agonist and IVIG.A 4‐year‐old girl saw the family physician with ecchymoses on the extremities and nasal bleeding. On laboratory analysis, platelets were 3 × 109/L, and platelet‐associated IgG concentration was 140 ng/107 cells. She was admitted to a local hospital and was diagnosed with primary ITP. IVIG with oral prednisolone therapy increased the platelet count temporarily to 50 × 109/L, but it decreased to 1 × 109/L within 1 week http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Pediatrics International Wiley

Eltrombopag with i.v. immunoglobulin for safe splenectomy in refractory immune thrombocytopenia

Loading next page...
 
/lp/wiley/eltrombopag-with-i-v-immunoglobulin-for-safe-splenectomy-in-refractory-3ysaaLkQKu
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
Copyright © 2018 Japan Pediatric Society
ISSN
1328-8067
eISSN
1442-200X
D.O.I.
10.1111/ped.13446
Publisher site
See Article on Publisher Site

Abstract

The first‐line treatment for pediatric immune thrombocytopenia (ITP) consists of observation, i.v. immunoglobulin (IVIG), or corticosteroids. Although these procedures resolve the condition in most affected children, some are refractory to treatment or relapse. Recent second‐line treatments, such as cyclosporin, rituximab or thrombopoietin receptor (TPO‐R) agonist are promising, but some patients do not respond well to them. Splenectomy remains the only salvage intervention that may induce a curative effect in nearly two‐thirds of such patients. We report a case of refractory ITP. The patient did not respond to first‐ and second‐line treatment. Concomitant use of eltrombopag and IVIG resulted in transient increase of platelet count and allowed a safer execution of splenectomy that resulted in remission of ITP. This is the first successful treatment of pediatric refractory ITP using TPO‐R agonist and IVIG.A 4‐year‐old girl saw the family physician with ecchymoses on the extremities and nasal bleeding. On laboratory analysis, platelets were 3 × 109/L, and platelet‐associated IgG concentration was 140 ng/107 cells. She was admitted to a local hospital and was diagnosed with primary ITP. IVIG with oral prednisolone therapy increased the platelet count temporarily to 50 × 109/L, but it decreased to 1 × 109/L within 1 week

Journal

Pediatrics InternationalWiley

Published: Jan 1, 2018

Keywords: ; ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off